Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a report released on ...

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) is set to release its Q4 2024 earnings on Feb 25, 2025. The consensus estimate for ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) – Equities research analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for Tarsus Pharmaceuticals in a report ...

Barclays lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $60 from $62 and keeps an Overweight rating on the shares ...

UI-TARS understands graphical user interfaces (GUIs), applies reasoning and takes autonomous, step-by-step action.

BofA lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $70 from $75 and keeps a Buy rating on the shares. Q4 capped off a ...

Tarsus Pharmaceuticals Inc (TARS) reports robust sales and strategic advancements, despite high operating expenses and market ...

In trading on Tuesday, shares of Tarsus Pharmaceuticals Inc (Symbol: TARS) entered into oversold territory, hitting an RSI reading of 26.7, after changing hands as low as $41.075 per share.

In this new study, the team in China has done just that with the development of UI-TARS—a GUI agent model that can be used locally on a personal computer or via the cloud on other devices.

TARS Project Management, a leading firm specialising in project management and digital transformation, has increased its stake in UMB Bank to 33 per cent, reinforcing its commitment to expanding ...